高脂血症是引发心脑血管疾病的关键因素，会导致动脉粥样硬化，严重威胁健康。当下治疗药物包含他汀类、贝特类、树脂类、烟酸及其衍生物等。其中，他汀类药物在降低低密度脂蛋白胆固醇（LDL-C）方面效果显著，近50年来，在动脉粥样硬化性心血管疾病（ASCVD）的防治上功不可没。然而，即便用到最大耐受剂量，仍有部分患者的LDL-C水平得不到有效控制。 这时，新型降脂药PCSK9 抑制剂应运而生，为血脂异常治疗 ...

The long-running legal dispute between Amgen and Sanofi/Regeneron on two key patents covering the use of PCSK9 inhibitors to lower cholesterol has come to an end, with Sanofi emerging as the victor.

AstraZeneca has reported the first clinical data with its oral PCSK9 inhibitor AZD0780, which it hopes could offer an alternative to current injectable drugs used to lower cholesterol. The new ...